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Accepted 19 January 2010AbstractObjective: The aim of this study was to identify an optimal stimulation protocol for intrauterine insemination (IUI) to obtain an acceptable
pregnancy rate and low frequency of multiple pregnancies.
Materials and Methods: In total, 340 patients, who received intrauterine insemination because of ovulation dysfunction, were enrolled in this
study. Group I consisted of 203 patients who received recombinant FSH (r-FSH) 150 U every other day as an ovulation induction agent. Group II
consisted of 137 patients who received r-FSH 100 U every other day as an ovulation induction agent. All patients in both groups also received
clomiphene citrate 100 mg/day for consecutive five days from the fifth day of the cycle. Only patients with at least two follicles >18 mm on the
human chorionic gonadotropin injection days were included in this study.
Results: The clinical pregnancy rate was 14.8% (30/203) in Group I compared with 20.4% (28/137) in Group II, p > 0.05. The incidence of
multiple pregnancy was 41.7% (10/24) in Group I compared with 12.5% (3/24) in Group II, p < 0.05.
Conclusions: The concurrent use of low-dose r-FSH and clomiphene citrate would seem not only to be cost-effective but also highly satisfactory
in that it prevents high-order multiple pregnancies.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Intrauterine insemination (IUI) is a common therapeutic
approach for couples who are suffering from a wide variety of
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doi:10.1016/j.tjog.2010.01.001or with ovulation stimulation. To increase the number of
oocytes and achieve a better pregnancy rate, controlled ovarian
hyperstimulation is usually performed in the majority of IUIs
[1,2]. However, significant variation in IUI clinical outcome
has been reported with different protocols of ovulation
induction. For example, when clomiphene citrate alone was
used for ovulation induction, the average pregnancy rate has
been reported to be below 10% per cycle in some studies [3,4].
When controlled ovarian hyperstimulation was performed
with gonadotropin, the average pregnancy rate has been
reported to be about 15% per cycle [5e7]. Although ovariancs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Comparison of age and semen quality between the two study groups
Group I Group II p
Age 31.9  3.0 31.3  3.1 >0.05
Total sperm count (106) 32.5  32.4 31.5  30.4 >0.05
Motility (%) 91.9  10.4 93.3  8.9 >0.05
Progressive motility (%) 51.3  21.1 53.9  22.5 >0.05
Group I: r-FSH 150 U; Group II: r-FSH 100 U.
Data are presented as mean  standard error of the mean.
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rate, it also carries the risk of the subject developing ovarian
hyperstimulation syndrome and/or having a high-order
multiple pregnancy [8e10]. To our knowledge, as yet, no
consensus exists about the drug of first choice to be used for
hyperstimulation.
Ideally, an IUI should be accomplished with a satisfactory
pregnancy rate per initiated cycle and a low risk of high-order
multiple pregnancies. To determine an optimal stimulation
dosage for IUI, a comparison of the clinical outcome in IUI
using two different protocols of gonadotropin for ovarian
stimulation was studied by retrospectively analysis.
Materials and methods
Under the approval of institutional review board in Chi Mei
Medical Center, we analyzed retrospectively IUI cycles using
husband’s sperm from January 2005 to November 2007. The
inclusion criteria were female subjects younger than 38 years
of age with a normal body mass index; furthermore, the
indication for IUI was anovulation. The couples with other
indications for IUI such as male factor, tube factor, and
unknown factor were excluded. Hysterosalpingography was
routinely used to evaluate the openness of the fallopian tubes.
Only patients with patent bilateral fallopian tubes were
included in this study. In total, we enrolled 340 patients for the
analysis. Patients were randomly enrolled into two groups.
Group I included 203 patients who received recombinant FSH
(r-FSH, Gonal-F; Serono, Geneva, Switzerland) 150 U every
other day from the 4th day to the 10th of the cycle as an
ovulation induction agent. Group II included 137 patients who
received r-FSH 100 U every other day from the 4th day to the
10th of the cycle as an ovulation induction agent. All patients
in both groups also received clomiphene citrate (CC; Clomi-
phene, Shinogi, Taiwan) 100 mg/day for five consecutive
days from the fifth day of the cycle as adjuvant stimulation.
A single IUI was then performed 36 hours after human
chorionic gonadotropin (Pregnyl, Organo, Oss, Holland)
administration. The primary outcomes were the clinical
pregnancy rate per cycle, the ongoing pregnancy rate (the
pregnancy with gestational age more than 12 weeks) per cycle,
and the multiple pregnancy rate per cycle. The outcomes are
presented as mean  SEM. c2 tests were used for statistics
analysis. Differences were considered statistically significant
at p < 0.05.
Semen preparation
Semen was prepared as previously described. Briefly, after
the semen was collected it was allowed to liquefy at 37C and
a small drop was placed in a Makler sperm counting chamber
(Sefi Medical Inc., Haifa, Israel) for evaluation. The remaining
of the specimen was suspended in 5 mL of a discontinuous
two-layer (40% and 80%) PureSperm solution gradient
(NidaCon International AB., Gothenburg, Sweden) and
centrifuged at 300g for 20 minutes. Sperm cells present in the
80% PureSperm layer were collected and washed twice insynthetic human tubal fluid. The final pellet was resuspended
in 0.5 mL of fresh human tubal fluid and was ready for IUI
with a Genitor catheter (Laboratory C.C.D., Paris, France).
A speculum was used to visualize the cervix, mucus was
removed with a cotton swab, the catheter was gently intro-
duced into the endometrial cavity, and the sample was slowly
injected. Patients were allowed to rest for 15 minutes after the
procedure. Each patient was prescribed 10 mg of oral dydro-
gesterone (Dyphastone, Duphar, Taiwan) three times a day
after the insemination. A urinary pregnancy test was used for
initial assessment of success 14 days later. Clinical pregnancy
was confirmed by identification of a positive fetal heartbeat
2 weeks later by transvaginal ultrasound examination.
Results
Across the 340 patients enrolled, the two treatment groups,
203 patients in Group I and 137 patients in Group II, were
similar with respect to mean age (31.9 3.0, Group I, compared
with 31.3  3.1, Group II). The total sperm count, sperm
motility, and percentage of sperm with progressive motility
were also similar between the treatment groups (Table 1). As
expected, there was a slight, but not significant, difference in the
number of follicle>18 mm in Group I compared with Group II
(5.1  3.6 vs. 4.3  1.9, p > 0.05).
Surprisingly, although statistically non-significant, the
clinical pregnancy rate and ongoing pregnancy rate were
higher in patients who received the lower dosage of ovulation
stimulation. The clinical pregnancy rate was 20.4% (24/137) in
the 100 IU Group compared with 14.8% (30/203) in the 150 IU
Group (p > 0.05). The ongoing pregnancy rate was 17.5% (24/
137) in the 100 IU Group compared with 11.8% (24/203) in
the 150 IU Group, p > 0.05. As expected, the incidence of
multiple pregnancy was statistically significant higher in the
150 IU Group than that in the 100 IU Group [41.7% (10/24) vs.
12.5% (3/24), p < 0.05, respectively]. Furthermore, there were
two triplet pregnancies and one quadruplet pregnancy in the
150 IU Group compared with no high-order multiple preg-
nancies in the 100 IU Group (Table 2).
Discussion
IUI is a common therapeutic approach for couples with
a wide variety of types of infertility. The overall pregnancy
rates for IUI vary greatly from as low as 5% to as high as 66%
[1]. IUI combined with ovarian hyperstimulation has long
Table 2
Comparison of the clinical outcomes between the two study groups
Group I Group II p
Follicle number 5.1  3.6 4.3  1.9 >0.05
Body mass index (kg/m2) 21.2  2.6 20.9  2.3 >0.05
Dose of gonadotrophins (IU) 533  242 513  184 >0.05
Clinical pregnancy rate 14.8% (30/203) 20.4% (28/137) >0.05
Ongoing pregnancy rate 11.8% (24/203) 17.5% (24/137) >0.05
Multiple pregnancy rate 41.7% (10/24) 12.5% (3/24) <0.05
7 Twins, 2 triplets,
1 quadruplets
3 Twins
Group I: r-FSH 150 IU; Group II: r-FSH 100 IU.
Data are presented as mean  standard error of the mean.
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subfertile couples [2]. Although IUI can be performed using
the natural cycle without any ovarian stimulation, previous
studies have suggested that there are higher pregnancy rates
per cycle when the patients are subjected to ovarian hyper-
stimulation [3,4,7]. CC, a traditional first-line oral ovulation
agent, can be used alone for ovulation induction in IUI.
However, many studies have shown that there is a higher
pregnancy rate in IUI cycles, compared with CC alone, when
gonadotropin stimulation is also used [11e13].
Human menopausal gonadotropin (HMG), a pharmaceutical
preparation from postmenopausal urine extracts, was most
popular for ovarian stimulation in the first few years. It was not
until 1996 that r-FSH preparations became available. These
preparations are completely lacking in any luteinizing hormone
activity or extraneous human protein and began to replace
HMG for ovulation stimulation [14]. Since then, many
comparisons of different ovarian stimulation protocols for IUI
have been described; nonetheless, there is no universal
consensus in terms of an optimal stimulation protocol [14e18].
Demirol and Gurgan [19] have suggested r-FSH would seem to
result in a better clinical pregnancy rate per IUI cycle than
urinary FSH and HMG. In their study, they found the r-FSH
group used a lower follicle-stimulating hormone dose and
produces more mature oocyte per cycle when compared with
the urinary FSH and HMG groups. On the other hand, Dankert
et al [20] declared that there was no significant difference in
live birth rates per IUI cycle between CC and r-FSH. However,
in their study, cycles with more than three follicles were
canceled. Despite all these conflicting results, r-FSH, which
greatly improved the clinical outcome in in vitro fertilization
and embryo transfer (IVF-ET) after it began to be used, indeed
attracted attention for use in IUI [21,22].
The major drawbacks of gonadotropin stimulation in IUI
are multiple gestation, ovarian hyperstimulation, and greater
expense of the treatment. Reducing the stimulation dosage to
a mild hyperstimulation protocol is obviously an option.
However, the cost-effectiveness of a mild stimulation protocol
needs to be carefully evaluated. For example, Goverde et al
[23] used 75 IU of follicle-stimulating hormone daily for
ovulation stimulation and found this mild stimulation protocol
did not result in a higher pregnancy rate than IUI using the
natural cycle, whereas at the same time multiple pregnanciescould not be avoided. Meanwhile, Ryan et al suggested that
combining an oral ovulation induction agent with low-dose
gonadotropin injections might be an ideal treatment for IUI
[24]. In his study, he gave oral medication followed by
gonadotropins before human chorionic gonadotropin and IUI
and found this combined protocol was less costly and equally
effective; furthermore, it potentially gave rise to fewer
multiple births than with gonadotropin alone.
In the past decade, scientists had tried many different
protocols to attempts to obtain an acceptable pregnancy rate,
a tolerable expense level for the treatment, and minimal risk of
a multiple pregnancy. In this context, it would seem that our
100 IU protocol fulfills the above requirements. In our study,
we simplified the combined protocol to consist of the
concurrent use of clomiphene citrate and r-FSH. The patients
were randomized into two groups, one of which received
clomiphene citrate with 100 IU of r-FSH stimulation for
4 days, whereas the other received clomiphene citrate with
150 IU of r-FSH stimulation for 4 days. The pregnancy rates
were 20.4% and 14.8%, respectively. Thus, we found that no
benefit was gained from the higher gonadotropin stimulation
dose during IUI, since the clinical pregnancy rate and ongoing
pregnancy rate were comparable between the two groups. We
also found when the gonadotropin stimulation dosage was
increased from 100 IU to 150 IU daily, this caused more
multiple pregnancies and more high-order multiple pregnan-
cies. The incidence of multiple pregnancies was 41.7% (10/24)
in the 150 IU Group compared with 12.5% (3/24) in 100 IU
Group (p < 0.05). Altogether, there were seven twin preg-
nancies, two triplet pregnancies, and one quadruplet preg-
nancy in the 150 IU Group compared with three twin
pregnancies and no high-order multiple pregnancy in the
100 IU Group. We attributed this result to the greater number
of mature follicles in 150 IU r-FSH group, although this was
statistically non-significant. Although this is a retrospective
study and therefore there are a number of pitfalls associated
with the approach, these results still give us some important
hints and broaden experience in this area.
An ideal stimulation protocol should be able to achieve
a satisfactory pregnancy rate with an acceptable multiple
pregnancy rate and without any high-order multiple pregnan-
cies if at all possible. From our experience, the combined use
of a low dose of r-FSH and clomiphene citrate is able to
achieve such a satisfactory pregnancy rate without any high-
order multiple pregnancies per initiated cycle. Accordingly,
we suggest this protocol be considered for IUI of infertile
couples with female ovulation dysfunction.References
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